4th Apr 2014 09:25
LONDON (Alliance News) - Hutchison China MediTech Ltd Friday said its majority-owned research and development company Hutchison MediPharma Ltd has initiated a Phase II clinical trial in colorectal cancer patients in China for fruquintinib.
Fruquintinib is the company's investigational small-molecule agent that selectively inhibits vascular endothelial growth factor receptors.
Preparations and patient screening began earlier this year, with the first patient dosed on April 2.
The randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with locally advanced or metastatic colorectal cancer, who have failed at least 2 prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan.
Approximately 70 patients are expected to be enrolled, with top-line results expected in 2015, Hutchison China MediTech said.
Meanwhile, Hutchison China MediTech said data from certain preclinical and clinical studies by Hutchison MediPharma will be presented at the annual meeting of the American Association for Cancer Research to be held in San Diego, California from April 5 to 9.
The presentations will include additional data on volitinib (HMPL-504/AZD6094) and epitinib (HMPL-813), two novel and highly selective small molecule drugs discovered by HMP, the company said.
Presentations on volitinib were prepared jointly with Hutchison MediPharma's collaboration partner AstraZeneca PLC, the company said.
Hutchison China MediTech shares were Friday quoted at 855.00 pence, up 3.0%.
By Samuel Agini; [email protected]; @samuelagini
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaHutchmed